Thus, the response of GLP-1 is blunted or reduced in obesity caused by dietary modulations [47], and GLP-1 agonists such as liraglutide and semaglutide (Ozempic) have been shown to improve weight loss, induce fat mass loss, and regulate lean muscle mass in obese human subjects [47]. Here, GCG is linked to obesity disorder.